A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-11-01
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-29 (study day 165); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-01 (study day 290); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-10 (study day 329); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-11 (study day 330); relationship: N
Data queries
No data queries.